--- title: "Goldenwell Biotech files late notice for June quarter report" url: "https://aibio.space/news/goldenwell-biotech-files-late-notice-june-quarter-report/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2025-08-14" section: "Distress" tickers: "OTC:GWLL" source: "https://www.sec.gov/Archives/edgar/data/1800373/000147793225005880/gdwl_nt10q.htm" summary: "Goldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has no" --- By the aibio.space news desk. Sources - [GOLDENWELL BIOTECH INC. NT 10-Q (2025-08-14)](https://www.sec.gov/Archives/edgar/data/1800373/000147793225005880/gdwl_nt10q.htm) - [Goldenwell Biotech, Inc. 10-K (2025-05-15): business and financial summary](https://www.sec.gov/Archives/edgar/data/1800373/000147793225003784/gdwl_10k.htm) [GWLL](https://aibio.space/companies/goldenwell-biotech/) 2025-08-14 # Goldenwell Biotech files late notice for June quarter report Tickers [GWLL](https://aibio.space/companies/goldenwell-biotech/) Goldenwell said it could not compile its financial information in time and expects to file by August 19, 2025. Its notice also says an annual report has not been filed, and its latest filed balance sheet is small. ## Key facts - **Company**: GOLDENWELL BIOTECH INC. (OTC: GWLL) - **News type**: Distress - **Primary source**: [GOLDENWELL BIOTECH INC. NT 10-Q (2025-08-14)](https://www.sec.gov/Archives/edgar/data/1800373/000147793225005880/gdwl_nt10q.htm) *Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.* ## The late quarterly report Goldenwell Biotech, Inc. told the Securities and Exchange Commission on August 14, 2025 that it could not file its quarterly report on Form 10-Q for the period ended June 30, 2025 on time. The company filed a Form 12b-25 notice, which gives a company a short automatic extension when it misses a deadline. For a quarterly report, the extension runs to the fifth calendar day after the due date. The notice says the company has been unable, without unreasonable effort or expense, to compile in time all the information for the financial statements and related disclosures that the quarterly report requires. It expects to file on or before August 19, 2025. The notice gives the company's address as 2071 Midway Dr., Twinsburg, Ohio, and names Hua Xie as the contact person. It gives no revenue, loss or cash figure for the quarter. ## A second report is also missing The form asks whether all other periodic reports due in the past 12 months have been filed. Goldenwell checked "No" and wrote that its Annual Report on Form 10-K for the fiscal year ended June 30, 2025 has not been filed. That wording does not match the company's own annual report filed on May 15, 2025, which says the fiscal year ends on December 31. The notice does not explain the difference or say when any annual report will be filed. The company also said it does not anticipate a significant change in results of operations from the same period of the last fiscal year. Because the notice carries no figures, that statement cannot be tested against numbers for the quarter. ## What the last annual report shows Goldenwell was incorporated on August 20, 2019 and has no subsidiaries. Its annual report says its business offices are at 581 Boston Mills Road, Suite 300, Hudson, Ohio, where it does not conduct operations and only receives mail. The summary financial information in that report, as of December 31, 2024, shows cash and cash equivalents of $49,404, total assets of $224,192, total liabilities of $271,433 and a stockholders' deficit of $(47,241). Liabilities therefore exceeded assets at that date. Those figures predate the quarter that is now late. The annual report says the company has five products and describes them as having completed three stages: an initial marketing analysis, research and development, and the parts of production, including selecting equipment and sources of raw materials. It says no special equipment needs to be engineered or produced and that the workforce it intends to hire will need training but no specialized education or experience. Those are the company's own statements. ## Products and licenses The first product the report lists is JI MAI, a bovine cardiac vascular active peptide in freeze-dried powder form. The second is Double Proline AG, a 3D active collagen peptide the company calls drinkable cosmetics, which it says has a molecular weight of 1920da. The third is a cartilage peptide, a type II collagen peptide. The products rest on two exclusive license agreements, both effective July 20, 2020. The first is with Australian Trefoil Health Technologies Pty Ltd and covers the technology and packaging designs underlying the Sugar Master and DNA Repair products and other products. It covers all territories except China, runs for the term of the underlying patent and expires on November 15, 2025. The report says Australian Trefoil is controlled by Li Yang, a director of the company. The second is with Ji Lin JZY Biotech Inc. and covers the technology the company uses in its products. It also covers all territories except China and expires on January 11, 2035. The report says Ji Lin JZY Biotech is controlled by Shang Liu, the company's President and Chief Executive Officer and a director. The company paid $10.00 for each license. Both licensors are therefore controlled by insiders, and the first license expires on November 15, 2025. The late notice does not say whether the company plans to renew it. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story GWLL GOLDENWELL BIOTECH INC. OTC ยท United States Open the starter desk ## More in Distress Distress ### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/) Oct 29, 2026 Distress ### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/) Oct 29, 2026 Distress ### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/) Oct 28, 2026 --- Source page: https://aibio.space/news/goldenwell-biotech-files-late-notice-june-quarter-report/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Goldenwell Biotech files late notice for June quarter report", 2025-08-14, https://aibio.space/news/goldenwell-biotech-files-late-notice-june-quarter-report/